摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)pyridine 1-oxide | 923288-11-3

中文名称
——
中文别名
——
英文名称
3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)pyridine 1-oxide
英文别名
3-Nitro-5-[3-(1-oxy-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-benzene-1,2-diol;2-Hydroxy-6-nitro-4-[3-(1-oxo-1lambda~5~-pyridin-3-yl)-1,2,4-oxadiazol-5(2H)-ylidene]cyclohexa-2,5-dien-1-one;3-nitro-5-[3-(1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]benzene-1,2-diol
3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)pyridine 1-oxide化学式
CAS
923288-11-3
化学式
C13H8N4O6
mdl
——
分子量
316.23
InChiKey
PMBPYLYFNUWBGF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    151
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Nitrocatechol Derivatives as Comt Inhibitors
    申请人:Learmonth David Alexander
    公开号:US20090054437A1
    公开(公告)日:2009-02-26
    New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.
    本文描述了一些公式I的新化合物。这些化合物在治疗某些中枢和周围神经系统疾病方面具有潜在的有价值的药物特性。
  • NITROCATECHOL DERIVATIVES AS COMT INHIBITORS
    申请人:Learmonth David Alexander
    公开号:US20120196904A1
    公开(公告)日:2012-08-02
    New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.
    本文描述了一种公式I的新化合物。这些化合物在治疗某些中枢和周围神经系统疾病方面具有潜在的有价值的药物特性。
  • Nitrocatechol derivatives as COMT inhibitors
    申请人:BIAL—PORTELA & CA, S.A.
    公开号:US10336740B2
    公开(公告)日:2019-07-02
    New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.
    本文描述了式 I 的新化合物。这些化合物在治疗某些中枢和周围神经系统疾病方面具有潜在的宝贵药用价值。
  • Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-<i>O</i>-methyltransferase
    作者:László E. Kiss、Humberto S. Ferreira、Leonel Torrão、Maria João Bonifácio、P. Nuno Palma、Patrício Soares-da-Silva、David A. Learmonth
    DOI:10.1021/jm1001524
    日期:2010.4.22
    Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the pyrazole core of the initial hit 4 with a 1,2,4-oxadiazole ring resulted in a series of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide residue at position 3 of the 1,2,4-oxadiazole ring led to analogue 37f, which was found to possess activity comparable to entacapone and lower toxicity in comparison to tolcapone. Lead structure 37f was systematically modified in order to improve selectivity and duration of COMT inhibition as well as to minimize toxicity. Oxadiazole 37d (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide (BIA 9-1067)) was identified as a long-acting, purely peripheral inhibitor, which is currently under clinical evaluation as an adjunct to L-Dopa therapy of Parkinson's disease.
  • EP2301934A1
    申请人:——
    公开号:EP2301934A1
    公开(公告)日:2011-03-30
查看更多